Leronlimab is a monoclonal antibody primarily investigated for its role in modulating the CCR5 receptor, which plays a key part in inflammatory and immune responses. It has been studied in the treatment of HIV, where it blocks the CCR5 co-receptor used by HIV to enter T-cells, offering a potential therapeutic option for patients with CCR5-tropic virus. Beyond HIV, leronlimab has been explored in oncology, particularly in metastatic triple-negative breast cancer, where it may help reduce tumor growth and metastasis by altering the tumor microenvironment and suppressing immune cell migration that supports cancer progression. It has also been evaluated in chronic graft-versus-host disease and autoimmune conditions due to its ability to influence immune cell trafficking. Clinical trials continue to assess its efficacy in inflammatory and immune-mediated diseases.